Gene Editing with CRISPR/Cas9: Advanced Topics

Published on :

Advanced Gene Editing with CRISPR is a 3-day hands-on workshop designed for researchers with entry level experience in CRISPR/Cas9 technology seeking a more in-depth immersion in state-of-art CRISPR applications such [….]

“DNA Valley” Continues to Flourish in Maryland, the Birthplace of the Human Genome Project

Published on :

Jeff Galvin, the CEO of American Gene TechnologiesⓇ, one of the leading biotech companies in Maryland, has championed the state as “DNA Valley.” And Galvin should know: he came to Maryland after a successful career in Silicon Valley and sees parallels between the early days of an emerging Silicon Valley and what’s going on today in DNA Valley, which currently stretches from Montgomery County and Frederick, Maryland all the way up to Baltimore.

Johns Hopkins University Partners with NIH, Howard University to Launch Medtech Accelerator

Published on :

Johns Hopkins University partners with NIH, Howard University to launch medtech accelerator Email Facebook LinkedIn Twitter Share article
NeuroTech Harbor Executive Director Sri Sarma views the project as a catalyst to turn Baltimore into a the Silicon Valley of neurological technology.
Courtesy of Sri Sarma
By Matt Hooke – Reporter
September 30, 2022, 02:24pm EDT
Johns Hopkins University is teaming with two Washington, D.C.-area institutions, Howard University and the National Institutes of Health, to create a new accelerator to help companies and research scientists focused on treating neurological conditions.
The nonprofit biotechnology accelerator, NeuroTech Harbor, is funded by an NIH investment of $5 million over five years, which could go up to $20 million annually. The NeuroTech Harbor plans to launch 45 new neurological companies over the next five years.
Executive director Sri Sarma, a professor at Hopkins, is seeking early stage companies to apply to the program. The goal is for companies to produce the first in-human prototype of a medical device by the end of the program. Selected companies can remain in the program for up to four years, earning $500,000 in support each year. Companies could be eligible for more support from the NIH if they succeed…

UMBC Professor Hopes His New NIH-Funded Research Can Speed up the Drug Approval Process

Published on :

UMBC professor hopes his new NIH-funded research can speed up the drug approval process Email Facebook LinkedIn Twitter Share article
Chengpeng Chen hopes that his research at UMBC can create a more accurate model of how human organs work, making it easier for drug companies in Baltimore and beyond to earn FDA approval.
Courtesy of UMBC
By Matt Hooke – Reporter
October 10, 2022, 07:32am EDT
A University of Maryland, Baltimore County professor hopes to rapidly speed up the drug approval process, making it easier for drugs to get to market and help patients.
In August, Chengpeng Chen earned a five-year, $1.7 million grant from the National Institutes of Health (NIH) to create a new way to model how drugs will impact human organs, starting with the liver. The device would shorten the time it takes to get U.S. Food and Drug Administration approval by providing a more accurate view of how drugs impact the human body than current testing methods. Baltimore is a hub for medical research, with several area pharmaceutical companies, such as MIRA1a Therapeutics and Alphyn Biologics earning substantial funding rounds. A faster way to get through the FDA approval process could be a boon to the…

The National Institutes of Health, a Technology Transfer Wellspring

Published on :

The National Institutes of Health (NIH) is a critical pillar of the U.S. public health system and a beacon of guidance for healthcare best practices across the globe. This has never been more evident than during the COVID-19 crisis. A lesser-known NIH facet is its long and productive history of technology transfer success.

Maryland Real Estate Roundup 2021

Collage with photos of Baltimore, Frederick, the Maryland flag, blue crabs, and text saying "Maryland Real Estate Roundup 2021"
Published on :

This year, Maryland continued to prove why it’s becoming one of the strongest biohealth clusters in the country. The state’s commitment to businesses in the life science, pharmaceutical, and biotech industries has continued as both the private and public sectors work to meet the demand for more space. Here are a few of the biggest real estate projects in Maryland in 2021. Some of these projects are still under construction, while others were unveiled this year. 

5 Questions with Kayla Valdes, Ph.D. Senior Manager, Horizon Therapeutics

Published on :

Dr. Kayla Valdes is a Senior Manager at Horizon Therapeutics, a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare diseases. Prior to joining Horizon, Dr. Valdes worked at the National Institutes of Health as a Senior Program Manager on the Cure Sickle Cell Initiative. She was also the Associate Director of Scientific Programs at the Drug Information Association (DIA), where she developed DIA’s global content strategy by providing scientific expertise in therapeutic drug development and regulatory policy.

BioHealth Capital Region Retains Strong Grip on No. 4 Spot of Top 10 U.S. Biopharma Hubs Eyes Third Spot by 2023

BioHealth Capital Region growth
Published on :

As a life sciences cluster, the BioHealth Capital Region is poised to become a top-three cluster in the Genetic Engineering & Biotechnology News (GEN) Top 10 Biopharma Clusters ranking on the strengths of early-stage companies becoming commercial successes and the construction of millions of square feet of new wet lab space.

BioHealth Innovation Adds Diane Ignar, Ph.D. and Dr. Loleta Robinson as NIH New Entrepreneurs-in-Residence

Published on :

BioHealth Innovation Inc. (BHI) announces the addition of Diane Ignar, Ph.D., and Dr. Loleta Robinson to the expanding Entrepreneurs-in-Residence (EIR) team. The Entrepreneur-in-Residence Program at BHI ensures that disruptive technologies receive all the resources required to transform the technology from a discovery into a commercially relevant product and eventually have a measurable impact on human health. The program was created to support scientists, early-stage startups, and licensed technologies to provide them with access to these resources. Diane will work with NIH’s National Institute on Aging, and Loleta will work with their Office of Extramural Research.

5 Questions with Stephanie M. Davis, Ph.D., Program Officer, National Heart, Lung, and Blood Institute

Published on :

“5 Questions With…” is a weekly BioBuzz series where we reach out to interesting people in the BioHealth Capital Region and beyond to share a little about themselves, their work, and maybe something completely unrelated. This week we welcome Stephanie M. Davis, Ph.D., Program Officer, National Heart, Lung, and Blood Institute. Stay tuned for more interviews with others from across the BioHealth Capital Region and beyond.